Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching

Eye

Volumn 18, Issue 3, 2004, Pages 269-277

  Reinhard, Thomas ^a   Bohringer D ^b   Enczmann, J ^b   Kogler G ^b   Mayweg, S ^b   Wernet, P ^b   Sundmacher, R ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Graft survival; HLA matching; HLA typing; Immune reaction; Keratoplasty

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CELL DENSITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; GENE LOCUS; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOGENETICS; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PENETRATING KERATOPLASTY; PROGNOSIS; SEROLOGY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE;

EID: 1842535243     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700636     Document Type: Article

References (46)

1. Zirm E. Eine erfolgreiche totale Keratoplastik. Graefe's Arch Clin Exp Ophthalmol 1906; 64: 581-593.
2. Hill JC. The use of cyclosporine in high risk keratoplasty. Am J Ophthalmol 1989; 107: 506-510.
3. Hill JC. Systemic cyclosporine in high risk keratoplasty. Short-versus long-term therapy Ophthalmology 1994; 101: 128-133.
4. Reinhard T, Hutmacher M, Sundmacher R, Godehardt E. Akute und chronische Immunreaktionen nach perforierender Keratoplastik mit normalem Immunrisiko. Klin Monatsbl Augenheilkd 1997; 210: 139-143.
5. Streilein J. Unraveling immune privilege. Science 1995; 270: 1158-1159.
6. Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci 1996; 36: 1530-1540.
7. Yamada J, Streilein JW. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber. Invest Ophthalmol Vis Sci 1997; 38: 2833-2843.
8. Sano Y, Okamoto S, Streilein JW. Induction of donor-specific ACAID can prolong orthotopic corneal allograft survival in 'high-risk' eyes. Curr Eye Res 1997; 16: 1171-1174.
9. Sundmacher R. Immunreaktionen nach Keratoplastik. Klin Monatsbl Augenheilkd 1977; 171: 705-722.
10. Sundmacher R, Stefansson A, Mackensen G. Verlaufsbeobachtungen nach Keratoplastik. Fortschr Ophthalmol 1983; 80: 224-227.
11. Opelz G, Mytilineos; J, Scherer S, Dunckley H, Trejaut J, Chapman J et al. Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation 1993; 55: 782-785.
12. Gibbs DC, Batchelor R, Werb A, Schlesinger W, Casey TA. The influence of tissue-type compatibility on the fate of full-thickness corneal grafts. Trans Ophthalmol Soc 1974; 94: 101-126.
13. Vannas S. Histocompatibility in corneal grafting. Invest Ophthalmol 1975; 14: 883-886.
14. Stark WJ, Hugh RT, Bias WB, Maumenee AE. Histocompatibility (HLA) antigens and keratoplasty. Am J Ophthalmol 1978; 86: 595-604.
15. Ehlers N, Kissmeyer-Nielsen F. Corneal transplantation and HLA histocompatibility. Acta Opthalmol 1979; 57: 738-741.
16. Foulks GN, Sanfilippo FP, Locasio JA, MacQueen JM, Dawson DV. Histocompatibility testing for keratoplasty in high-risk patients. Ophthalmology 1983; 90: 239-244.
17. Sanfilippo F, MacQueen JM, Vaughn WK, Foulks GN. Reduced graft rejection with good HLA-A and -B matching in high-risk corneal transplantation. New Engl J Med 1986; 315: 29-35.
18. Völker-Dieben HJ, D'Amaro J, Kruit PJ, Lange P. Interaction between prognostic factors for corneal allograft survival. Transplant Proc 1989; 21: 3135-3138.
19. Boisjoly HM, Roy R, Bernard PM, Dubé I, Laughrea. PA, Bazin R. Association between corneal allograft reactions and HLA compatibility. Ophthalmology 1990; 97: 1689-1698.
20. Baggesen K, Ehlers N, Lamm LU. HLA-DR/RFLP compatible corneal grafts. Acta Ophthalmol 1991; 69: 229-233.
21. Beekhuis WH, van Rij G, Renardel de Lavalette JG, Rinkelvan Driel E, Persijn G, D'Amaro J. Corneal graft survival in HLA-A-and HLA-B-matched transplantations in high-risk cases with retrospective review of HLA-DR compatibility. Cornea 1991; 10: 9-12.
22. CCTS. Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992; 110: 1392-1403.
23. Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ. Conclusions of the corneal transplant follow up study. Br J Ophthalmol 1997; 81: 631-636.
24. Hoffmann F, Pahlitzsch T. Predisposing factors in corneal graft rejection. Cornea 1989; 8: 215-219.
25. Hoffmann F, Tregel M, Noske W, Bünte S. HLA-B and -DR match reduces the allograft rejection after keratoplasty. Ger J Ophthalmol 1994; 3: 100-104.
26. Gore SM, Vail A, Bradley BA, Rogers CA, Easty DL, Armitage WJ. HLA-DR matching in corneal transplantation: Systematic review of published data. Transplantation 1995; 110: 1392.
27. Reinhard T, Sundmacher R, Heering P. Systemic Cyclosporin A in high-risk keratoplasties. Graefe's Arch Clin Exp Ophththalmol 1996; 234 (Suppl 1): 115-121.
28. Hopkins KA, Maguire MG, Fink NE, Bias WB. Reproducibility of HLA-A, -B, and -DR typing using peripheral blood samples: Results of retyping in the CCTS. Hum Immunol 1992; 22: 132.
29. Völker-Dieben HJ, Claas FHJ, Schreuder GMT, Schipper RF, Pels E, Persijn GG, Smits J, D'Amaro J, Beneficial effect of HLA-DR matching on the survival of corneal allografts. Transplantation 2000; 70: 640-648.
30. Wernet P, Kögler G, Enczmann L Kuhröber A, Knipper A, Bonte W, Reinhard T, Sundmacher R. Rapid method for successful HLA Class I and II typing from cadaveric blood for direct matching in cornea transplantation. Graefe's Arch Clin Exp Ophthalmol 1998; 236: 507-512.
31. Pels L, Maas H, Tullo A. European Eye Bank Association Directory, 8th ed., 2000, EEBA, Amsterdam.
32. Böhnke M. Spendergewebe für die Keratoplastik. Klin Monatsbl Augenheilkd 1991; 198: 563-571.
33. Reinhard T, Holzwarth D, Spelsberg H, Dahmen N, Sundmacher R. Wissensbasierte Bildanalyse von Hornhauttransplantaten. Klin Monatsbl Augenheilkd 1999; 214: 407-411.
34. Hoffmann F. Nahttechnik bei perforierender Keratoplastik. Klin Mbl Augenheilk 1976; 169: 584-590.
35. Allredge OC, Krachmer JH. Clinical types of corneal transplant reaction. Arch Ophthalmol 1981; 99: 599-604.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
37. Armitage WJ, Easty DL. Factors influencing the suitability of organ-cultured corneas for transplantation. Invest Ophthalmol Vis Sci 1997; 38: 16-24.
38. Borderie VM, Scheer S, Touzeau. O. Donor organ cultured corneal tissue selection before penetrating keratoplasty. Br J Ophthalmol 1998; 82: 382-388.
39. Streilein JW. Immunobiology and immunopathology of corneal transplantation. In: Streilein JW (ed). Immune Response and the Eye. Chem Immunol, Vol 79. Karger: Basel, 1999, pp 186-206.
40. Newsome DA, Takasugi M, Kenyon K, Stark WF, Opelz G. Human corneal cells in vitro: Morphology and histocompatibility antigens of pure cell populations. Invest Ophthalmol Vis Sci 1974; 13: 23-32.
41. Jager M. Corneal Langerhans cells and ocular immunology. Regional Immunol 1992; 4: 186-195.
42. Donelly JJ, Li W, Rockey JH, Prendergast RA. Induction of class II alloantigen expression on corneal endothelium in vivo and in vitro. Invest Ophthalmol Vis Sci 185; 26: 575-580.
43. Young E, Stark WJ, Prendergast RA. Immunology of corneal allograft rejection: HLA-DR antigens on human corneal cells. Invest Ophthalmol Vis Sci 1985; 26: 571-574.
44. Vilcek J, Jumming L. Inferon gamma. In: Delves PJ, Roitt IM (eds). Encyclopedia of Immunology. Academic Press: San Diego, 1999, pp 1421-1426.
45. Reis A, Megahed H, Reinhard T, Godehardt E, Spelsberg H, Braunstein S et al. Coadministration of the new macrolide RAD and Mycophenolate mofetil. in experimental corneal transplantation. Transplantation 2000; 70: 1397-1401.
46. Beekhuis WH. Langzeitergebnisse bei HLA-A und B gematchter Hochrisiko-Keratoplastik. Ophthalmologe 2001; 98: S6-S7.